Post-Orchiectomy Management

Seminoma Management

85% Stage I, 10% Stage II, 5% Stage III at presentation

Stage I

Stage II/III

Post-chemotherapy residual masses


Nomogram to predict probability of teratoma in pcRPLND specimen, from Calaway 2021

NSGCT Management

33% Stage I, 33% Stage II, 33% Stage III at presentation

Stage IA-IB

Stage IS

Stage IIA

Stage IIB

Stage IIC + III

Post-chemotherapy residual masses

Relapsed disease

Brain metastases